E-learning: Treatment of Mantle Cell Lymphoma (MCL): Focusing on BTK Inhibitors

Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)
- Introduction
- Incidence and prevalence
- Causes and risk factors
- Symptoms and diagnosis
- Stages and grades
Treatment landscapes of MCL
Current treatment guidelines for MCL
First-line therapy
- Treatment strategies for fit patients with MCL
- Treatment strategies for frail patients with MCL
Treatment options for relapsed/refractory (R/R) MCL – Second-line treatment options
- Early relapses
- Late relapses
- BTK inhibitors
- Other treatment in R/R MCL
- Future directions (ongoing trials in R/R MCL)
Real-world experience with ibrutinib in R/R MCL
Treatment options for patients progressing after second-line ibrutinib
Emerging treatments under investigation for R/R MCL
CAR T-cell therapy for R/R MCL: brexucabtagene autoleucel
Summary/take home messages